Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC)
Commercial Sponsor
Merck
Summary
Eligible participants will be randomised to receive 400mg of intravenous pembrolizumab or a placebo on Day 1 of each 42-day cycle (Q6W) for up to 9 cycles. Participants, treated with either pembrolizumab or the placebo, who experience biopsy-proven-disease recurrence may be eligible to receive up to 18 cycles of pembrolizumab in an open-label design.